Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors.

Autor:	Lin H; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Wang M; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Zhang YW; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Tong S; VIVA Biotech Ltd., 334 Aidisheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China., Leal RA; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Shetty R; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Vaddi K; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States., Luengo JI; Prelude Therapeutics, 200 Powder Mill Road, Wilmington, Delaware 19803, United States.
Jazyk:	angličtina
Zdroj:	ACS medicinal chemistry letters [ACS Med Chem Lett] 2019 May 22; Vol. 10 (7), pp. 1033-1038. Date of Electronic Publication: 2019 May 22 (Print Publication: 2019).
DOI:	10.1021/acsmedchemlett.9b00074
Abstrakt:	Protein arginine methyltransferase 5 (PRMT5) is known to symmetrically dimethylate numerous cytosolic and nuclear proteins that are involved in a variety of cellular processes. Recent findings have revealed its potential as a cancer therapeutic target. PRMT5 possesses a cysteine (C449) in the active site, unique to PRMT5. Therefore, covalent PRMT5 inhibition is an attractive chemical approach. Herein, we report an exciting discovery of a series of novel hemiaminals that under physiological conditions can be converted to aldehydes and react with C449 to form covalent adducts, which presumably undergo an unprecedented elimination to form the thiol-vinyl ethers, as indicated by electron density in the co-crystal structure of the PRMT5/MEP50 complex. Competing Interests: The authors declare no competing financial interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu